Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | SYK | P43405 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 7/20 | 0.34 |
| ▸ | JAK1 | P23458 | 7/20 | 0.34 |
| ▸ | JAK3 | P52333 | 7/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16177403 | 0.83 | KDM5A (0.38) | MAPK1SYKJAK2JAK1JAK3 | |
| SCHEMBL14795168 | 0.72 | SYK (0.43) | SYKJAK2JAK1JAK3 | |
| SCHEMBL14795112 | 0.71 | SYK (0.46) | SYKJAK2JAK1JAK3 | |
| SCHEMBL2319051 | 0.71 | JAK3 (0.51) | MAPK1JAK2JAK1JAK3 | |
| SCHEMBL2318322 | 0.69 | MAPK1 (0.40) | MAPK1SYKJAK2JAK1JAK3 | |
| SCHEMBL1934552 | 0.67 | JAK2 (0.38) | MAPK1SYKJAK2JAK1JAK3 | |
| SCHEMBL22941145 | 0.66 | MAPK1 (0.52) | MAPK1 | |
| SCHEMBL2340266 | 0.66 | JAK3 (0.51) | SYKJAK2JAK1JAK3 | |
| SCHEMBL14795166 | 0.64 | SYK (0.41) | SYKJAK2JAK1JAK3 | |
| SCHEMBL2317953 | 0.64 | CA1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| WO-2014169473-A1 | 6H-IMIDAZO[1,5-a]PYRROLO[2,3-e]PYRAZINE COMPOUNDS | ABBVIE INC. (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140315883-A1 | 6H-IMIDAZO[1,5-a]PYRROLO[2,3-e]PYRAZINE COMPOUNDS | ABBVIE INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315883-A1 | 6H-IMIDAZO[1,5-a]PYRROLO[2,3-e]PYRAZINE COMPOUNDS | IL5, IL2, IL15 | MAPK1 1496/4885SYK 1750/4885JAK2 49/4885 |
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | CCNI, IL2, IL4I1 | MAPK1 1973/4885SYK 1996/4885JAK2 206/4885 |
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | MAPK1 1973/4885SYK 1996/4885JAK2 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.